In a randomized, double-blind placebo-controlled trial, 40 patients diagnosed as subcortical vascular encephalopathy (SVE) were given a daily dose of 500 ml i.v. amantadine vs. placebo for 5 days. Both groups were treated with physiotherapy on a daily basis. Quantitative gait analyses were performed at days 1 and 6 to evaluate gait steadiness from cadence, length of heel-to-toe movements, variability of centre of gravity (COG) and double support time. Both placebo- and amantadine-receiving patient groups showed mild improvement in gait parameters after study, which failed to show the superiority of amantadine, when comparing drug-induced changes between both groups. However, analysing the treatment effects from day 0 to day 6 in both groups separately, statistically significant changes could be found in the amantadine group for cadence, length of heel-to-toe movements in single support phase as well as for variability in double support phase and double support time (two-tailed paired t-test, p < 0.05), whereas in the placebo group, a statistically significant effect could only be seen for double support time (p < 0.05). In this small pilot study, amantadine tends to improve gait steadiness as evaluated by cadence, length of heel-to-toe movements in single support phase, variability in double support phase and double support time, in patients with moderate frontal gait disorder due to SVE. Improvements in the placebo group can be interpreted as physiotherapy effect, which improved gait steadiness slightly, however, this was statistically significant only for double support time.

1.
Jackisch R, Link T, Neufang B, Koch R: Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: No evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Thér 1992;320:21–42.
2.
Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ: Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 1992;263:717–724.
3.
Kornhuber J, Weller M: Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997;41:135–144.
4.
Stoof JC, Booij J, Drukarch B: Amantadine as N-methyl-D-aspartic acid receptor antagonist: New possibilities for therapeutic applications? Clin Neurol Neurosurg 1992;94(suppl):4–6.
5.
Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA: Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992;12:4427–4436.
6.
Lees KR: Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49(suppl):66–69.
7.
Cummings JL: Vascular subcortical dementias: Clinical aspects. Dementia 1994;5:177–180.
8.
Hennerici MG, Oster M, Cohen S, Schwartz A, Motsch L, Daffertshofer M: Are gait disturbances and white matter degeneration early indicators of vascular dementia? Dementia 1994;5:197–202.
9.
Oster M, Cohen SA, Gass A, Kischka U, Schwartz A, Hennerici M: Neuropsychological instruments for grading of subcortical vascular encephalopathy. Cerebrovasc Dis 1995;5:270.
10.
Gass A, Oster M, Cohen S, Daffertshofer M, Schwartz A, Hennerici MG: Assessment of T2- and T1-weighted MRI brain lesion load in patients with subcortical vascular encephalopathy. Neuroradiology 1998;40:503–506.
11.
Baezner H, Oster M, Daffertshofer M, Hennerici M: Assessment of gait in subcortical vascular encephalopathy through computerized analysis – A cross-sectional and longitudinal study. J Neurol 2000;415:841–849.
12.
Goetz CG: New lessons from old drugs. Neurology 1998;50:1211–1212.
13.
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 1998;50:1323–1326.
14.
Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvez-Jimenez N: New use for an old drug: Amantadine benefits levodopa-induced dyskinesia. Mov Disord 1998;13:851.
15.
Blanchet PJ, Konitsiotis S, Chase TN: Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798–802.
16.
Factor SA, Molho ES, Brown DL: Acute delirium after withdrawal of amantadine in Parkinson’s disease. Neurology 1998;50:1456–1458.
17.
Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P: Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. Eur J Pharmacol 1991;206:297–300.
18.
Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P: Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995;34:713–721.
19.
Thompson PD, Marsden CD: Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger’s disease. Mov Disord 1987;2:1–8.
20.
Masdeu JC, Wolfson L, Kantos G, Tobin J, Grober E, Whipple R, Amerman P: Brain white matter changes in the elderly prone to falling. Arch Neurol 1989;46:1292–1296.
21.
Nutt JG, Marsden CD, Thompson PD: Human walking and higher-level gait disorders, particularly in the elderly. Neurology 1993;43:268–279.
22.
Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P: Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 1999;34:313–318.
23.
Toide K: Effects of amantadine on dopaminergic neurons in discrete regions of the rat brain. Pharm Res 1990;7:670–672.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.